目次
Table of Content
1. Introduction To Controlled Drug Delivery
1.1 Fundamentals and Technology
1.2 Classification By System, Route and Technology
1.3 Mechanisms Of Action
2. Material Based Approaches For Controlled Drug Delivery
2.1 Polymers
2.2 Chronopharmaceutics
2.3 Nanoparticulate Delivery System
3. Global Controlled Release Drug Delivery Market Trends
3.1 Current Market Scenario
3.2 Future Market Outlook
4. Controlled Drug Delivery Research and Clinical Trends By Indication
4.1 Neurological Disorders
4.2 Cardiovascular Diseases
4.3 Diabetes
4.4 Cancer
4.5 Microbial Infections
5. Global Controlled Release Drug Market Trends By Region
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 Canada
5.6 South Korea
6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication and Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered
7. Marketed Controlled Release Drugs Clinical Insight By Company, Country and Indication
8. Controlled Release Drugs for Alzheimer’s Disease - Pricing and Dosage Insight
8.1 Namzaric (Extended-Release)
8.2 Namenda XR (Extended-Release)
8.3 Razadyne ER (Extended Release)
9. Controlled Release Drugs for Parkinson’s Disease - Pricing and Dosage Insight
9.1 Gocovri (Extended-Release)
9.2 Osmolex ER (Extended-Release)
9.3 Mirapex ER (Extended-Release)
10. Controlled Release Drugs for Schizophrenia - Pricing and Dosage Insight
10.1 Invega (Extended-Release)
10.2 Invega Franchise/Invega Hafyera (Extended-Release)
10.3 Seroquel XR (Extended-Release)
10.4 Abilify Franchise (Extended-Release)
10.5 Aristada/Aristada Initio (Extended-Release)
10.6 Rykindo (Extended-Release)
10.7 Risperdal Consta (Extended-Release)
10.8 Uzedy (Extended-Release)
11. Controlled Release Drugs for Chronic and Post-Operative Pain - Pricing and Dosage Insight
11.1 Hysingla ER (Extended-Release)
11.2 Nucynta ER (Extended-Release)
11.3 Kadian (Extended-Release)
11.4 Xtampza ER (Extended-Release)
11.5 MS Contin (Extended-Release)
11.6 Embeda (Extended-Release)
11.7 Posimir (Sustained-Release)
11.8 Zynrelef (Extended-Release)
11.9 ConZip (Extended-Release)
11.10 Generic Hydromorphone (Extended-Release)
12. Controlled Release Drugs for Multiple Sclerosis - Pricing and Dosage Insight
12.1 Ampyra / Fampyra (Extended-Release)
12.2 Tecfidera (Delayed-Release)
12.3 Vumerity (Delayed-Release)
12.4 Rayos (Delayed-Release)
12.5 Bafiertam (Delayed-Release)
13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing and Dosage Insight
13.1 Glumetza (Extended-Release)
13.2 Glucotrol XL (Extended-Release)
13.3 Glucophage XR (Extended-Release)
13.4 Trijardy XR (Extended-Release)
13.5 Synjardy XR (Extended-Release)
14. Controlled Release Drugs for Cardiovascular Diseases - Pricing and Dosage Insight
14.1 Procardia XL (Extended-Release)
14.2 Toprol XL (Extended-Release)
14.3 Verelan PM (Extended-Release)
14.4 Cardizem LA (Extended-Release)
14.5 Calan SR (Sustained-Release)
14.6 Altoprev (Extended-Release)
14.7 Cardura XL (Extended-Release)
15. Controlled Release Drugs for HIV - Pricing and Dosage Insight
15.1 Apretude (Extended-Release)
15.2 Cabenuva (Extended-Release)
15.3 Rukobia (Extended-Release)
16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing and Dosage Insight
16.1 Qelbree (extended-release)
16.2 Jornay PM (Extended-Release)
16.3 Cotempla XR-ODT (Extended-Release)
16.4 Adzenys XR-ODT (Extended-Release)
16.5 Intuniv (Extended-Release)
16.6 Focalin XR (Extended-Release)
17. Controlled Release Drugs for Inflammatory and Autoimmune Diseases - Pricing and Dosage Insight
17.1 Rinvoq (Extended-Release)
17.2 Ortikos (Extended-Release)
17.3 Xeljanz XR (Extended-Release)
17.4 Mestinon Timespan (Extended-Release)
17.5 Symax Duotab (Extended-Release)
18. Controlled Release Drugs for Bacterial Infections - Pricing and Dosage Insight
18.1 Aemcolo (Delayed-Release)
18.2 Talicia (Delayed-Release)
19. Controlled Release Drugs for Opioid Use Disorder - Pricing and Dosage Insight
19.1 Sublocade (Sustained-Release)
19.2 Brixadi (Extended-Release)
20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing and Dosage Insight
20.1 Astagraf XL (Extended-Release)
20.2 Envarsus XR (Extended-Release)
21. Controlled Release Drugs for Migraine and Seizure - Pricing and Dosage Insight
21.1 Trokendi XR (Extended-Release)
21.2 Oxtellar XR (Extended-Release)
21.3 Keppra XR (Extended-Release)
21.4 Roweepra XR (Extended-Release)
21.5 Depakote, Depakote ER, and Depakote Sprinkles
22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing and Dosage Insight
22.1 Effexor XR (Extended-Release)
22.2 Xanax XR (Extended-Release)
22.3 Ambien CR (Extended-Release)
23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing and Dosage Insight
23.1 Klor-Con 8, Klor-Con 10, Klor-Con M10, Klor-Con M15, Klor-Con M20
24. Global Controlled Drug Delivery System Market Dynamics
24.1 Market Drivers and Opportunities
24.2 Market Challenges and Restraints
25. Competitive Landscape
25.1 AbbVie
25.2 Antlia Bioscience
25.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
25.4 AstraZeneca
25.5 Bausch Health Companies
25.6 Biodexa Pharmaceuticals
25.7 Boehringer Ingelheim
25.8 Camurus
25.9 DURECT Corporation
25.10 Emplicure
25.11 HLK Pharmacin
25.12 Jemincare
25.13 Johnson and Johnson
25.14 Luye Pharma Group
25.15 Lyndra
25.16 Mallinckrodt plc
25.17 MedinCell S.A.
25.18 Merck
25.19 Otsuka Pharmaceutical
25.20 Pacira BioSciences
25.21 Pfizer
25.22 Purdue Pharma
25.23 Roche
25.24 Sanofi
25.25 Serina Therapeutics
25.26 Sun Pharmaceutical Industries
25.27 Supernus Pharmaceuticals
25.28 Takeda
25.29 Tris Pharma
25.30 ViiV Healthcare
List of Figures
Figure 1-1: Conventional Drug Delivery Systems - Limitations
Figure 1-2: Novel Drug Delivery Platform Diversification
Figure 1-3: Evolution Of Drug Delivery Technology: 1st to 3rd Generation
Figure 1-4: Challenges Addressed By Third Generation Drug Delivery
Figure 1-5: Targeted vs. Non-Targeted Drug Delivery
Figure 1-6: Zero-Order Controlled Drug Release
Figure 1-7: Plasma Concentration-Time Profile: Conventional vs. Controlled Release
Figure 1-8: Comparison Of Modified Drug Release Systems
Figure 1-9: Pulsatile Drug Release Mechanism In Pulsincap
Figure 1-10: Classification By Technical Complexity
Figure 1-11: Structural Differences Among Drug Delivery Systems
Figure 1-12: Classification By Route of Administration
Figure 1-13: Types Of Diffusion-Controlled Mechanisms
Figure 1-14: Encapsulation Dissolution-Controlled Mechanism
Figure 1-15: Osmotic Controlled Drug Release
Figure 1-16: Erosion Mechanisms In Matrix Systems
Figure 2-1: Polymeric Controlled Drug Delivery Devices - Categories
Figure 2--2: Nanostructures For Nanoparticulate Delivery Systems
Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2022 - 2025
Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2026 - 2030
Figure 4-1: Major Non-Invasive Routes For Insulin Delivery
Figure 4-2: Controlled Drug Delivery Strategies In Cancer Therapy
Figure 6-1: Global - Controlled Release Drug Clinical Pipeline By Phase (Number), 2025 Till 2030
Figure 8-1: Namzaric - Price Per Unit and Supply (US$), August’2025
Figure 8-2: Generic Donepezil/Memantine - Price Per Unit and Supply (US$), August’2025
Figure 8-3: Namenda XR - Price Per Unit and Supply Of 7mg and 21mg Extended Release Capsules (US$), August’2025
Figure 8-4: Namenda XR - Price Per Unit and Supply Of 14mg and 28mg Extended Release Capsules (US$), August’2025
Figure 8-5: Namenda XR - Price Per Unit and Supply Of Extended Release Oral Kit (US$), August’2025
Figure 8-6: Generic Memantine - Price Per Unit and Supply Of 7mg and 21mg Extended Release Capsules (US$), August’2025
Figure 8-7: Generic Memantine - Price Per Unit and Supply Of 14mg Extended Release Capsules (US$), August’2025
Figure 8-8: Generic Memantine - Price Per Unit and Supply Of 28mg Extended Release Capsules (US$), August’2025
Figure 8-9: Razadyne ER - Price Per Unit and Supply (US$), August’2025
Figure 8-10: Generic Galantamine - Price Per Unit and Supply (US$), August’2025
Figure 9-1: Gocovri - Price Per Unit and Supply (US$), August’2025
Figure 9-2: Global - Gocovri Annual Sales (US$ Million), 2021-2025
Figure 9-3: Global - Gocovri Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 9-4: Global - Gocovri Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 9-5: Osmolex ER - Price Per Unit and Supply Of 322 mg Extended Release Tablet (US$), August’2025
Figure 9-6: Osmolex ER - Price Per Unit and Supply Of 129 mg Extended Release Tablet (US$), August’2025
Figure 9-7: Osmolex ER - Price Per Unit and Supply Of 193 mg Extended Release Tablet (US$), August’2025
Figure 9-8: Osmolex ER - Price Per Unit and Supply Of 258 mg Extended Release Tablet (US$), August’2025
Figure 9-9: Mirapex ER - Available Dosage Strengths (mg)
Figure 9-10: Mirapex ER - Price Per Unit and Supply Of 0.375 mg and 0.75 mg Extended Release Tablets (US$), August’2025
Figure 9-11: Mirapex ER - Price Per Unit and Supply Of 1.5 mg Extended Release Tablet (US$), August’2025
Figure 9-12: Mirapex ER - Price Per Unit and Supply Of 2.25 mg, 3 mg, 3.75 mg and 4.5 mg Extended Release Tablets (US$), August’2025
Figure 9-13: Generic Pramipexole - Price Per Unit and Supply Of 0.375 mg and 0.75 mg (US$), August’2025
Figure 9-14: Generic Pramipexole - Price Per Unit and Supply Of 1.5 mg, 2.25 mg, 3 mg, and 4.5 mg (US$), August’2025
Figure 9-15: Generic Pramipexole - Price Per Unit and Supply Of 3.75 mg (US$), August’2025
Figure 10-1: Invega - Available Dosage Strengths (mg)
Figure 10-2: Invega - Price Per Unit and Supply (US$), August’2025
Figure 10-3: Invega Sustenna - Price Per Unit and Supply (US$), August’2025
Figure 10-4: Invega Trinza - Price Per Unit and Supply (US$), August’2025
Figure 10-5: Invega Hafyera - Price Per Unit and Supply (US$), August’2025
Figure 10-6: Global - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-7: Global - Invega Franchise Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 10-8: Global - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 10-9: US - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-10: US - Invega Franchise Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 10-11: US - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 10-12: ROW - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-13: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 10-14: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 10-15: Seroquel XR - Available Dosage Strengths (mg)
Figure 10-16: Seroquel XR - Price Per Unit and Supply (US$), August’2025
Figure 10-17: Generic Quetiapine - Price Per Unit and Supply Of 60 Tablets (US$), August’2025
Figure 10-18: Generic Quetiapine - Price Per Unit and Supply Of 100 Tablets (US$), August’2025
Figure 10-19: Global - Seroquel XR Total Annual Sales (US$ Million), 2020-2021
Figure 10-20: Abilify Maintena - Available Dosage Strengths (mg)
Figure 10-21: Abilify Maintena - Price Per Supply of Vial and Prefilled Syringe (US$), August’2025
Figure 10-22: Abilify Asimtufii - Price Per Unit and Supply (US$), August’2025
Figure 10-23: Global - Abilify Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-24: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 10-25: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 10-26: Aristada - Available Dosage Strengths (mg)
Figure 10-27: Aristada - Price Per Unit and Supply (US$), August’2025
Figure 10-28: Aristada Initio - Price Per Unit and Supply (US$), August’2025
Figure 10-29: Global - Aristada Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-30: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 10-31: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 10-32: Rykindo - Available Dosage Strengths (mg)
Figure 10-33: Rykindo - Price Per Supply (US$), August’2025
Figure 10-34: Generic Risperidone - Price Per Supply (US$), August’2025
Figure 10-35: Risperdal Consta - Price Per Supply (US$), August’2025
Figure 10-36: Global - Risperdal Consta Annual Sales (US$ Million), 2020-2021
Figure 10-37: Uzedy - Price Per Unit and Supply (US$), August’2025
Figure 11-1: Hysingla ER - Available Dosage Strengths (mg)
Figure 11-2: Hysingla ER - Price Per Unit and Supply (US$), August’2025
Figure 11-3: Generic Hydrocodone - Price Per Unit and Supply (US$), August’2025
Figure 11-4: Nucynta ER - Available Dosage Strengths (mg)
Figure 11-5: Nucynta ER - Price Per Unit and Supply (US$), August’2025
Figure 11-6: Global - Nucynta ER Annual Sales (US$ Million), 2020-2025
Figure 11-7: Global - Nucynta ER Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-8: Global - Nucynta ER Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-9: Kadian - Available Dosage Strengths (mg)
Figure 11-10: Kadian - Price Per Unit and Supply Of Strength 10 mg/12 hr (US$), August’2025
Figure 11-11: Kadian - Price Per Unit and Supply Of Strength 10 mg/12 to 24 hr and 10 mg/24 hr (US$), August’2025
Figure 11-12: Kadian - Price Per Unit and Supply Of Strength 20 mg/12 hr (US$), August’2025
Figure 11-13: Kadian - Price Per Unit and Supply Of Strength 20 mg/12 to 24 hr and 20 mg/24 hr (US$), August’2025
Figure 11-14: Kadian - Price Per Unit and Supply Of Strength 30 mg/12 hr (US$), August’2025
Figure 11-15: Kadian - Price Per Unit and Supply Of Strength 30 mg/12 to 24 hr and 30 mg/24 hr (US$), August’2025
Figure 11-16: Kadian - Price Per Unit and Supply Of Strength 40 mg/12 to 24 hr and 40 mg/24 hr (US$), August’2025
Figure 11-17: Kadian - Price Per Unit and Supply Of Strength 50 mg/12 hr (US$), August’2025
Figure 11-18: Kadian - Price Per Unit and Supply Of Strength 50 mg/12 to 24 hr and 50 mg/24 hr (US$), August’2025
Figure 11-19: Kadian - Price Per Unit and Supply Of Strength 60 mg/12 hr (US$), August’2025
Figure 11-20: Kadian - Price Per Unit and Supply Of Strength 60 mg/12 to 24 hr (US$), August’2025
Figure 11-21: Kadian - Price Per Unit and Supply Of Strength 60 mg/24 hr (US$), August’2025
Figure 11-22: Kadian - Price Per Unit and Supply Of Strength 70 mg/12 to 24 hr (US$), August’2025
Figure 11-23: Kadian - Price Per Unit and Supply Of Strength 80 mg/12 hr, 80 mg/12 to 24 hr and 80 mg/24 hr (US$), August’2025
Figure 11-24: Kadian - Price Per Unit and Supply Of Strength 100 mg/12 hr, 100 mg/12 to 24 hr and 100 mg/24 hr (US$), August’2025
Figure 11-25: Kadian - Price Per Unit and Supply Of Strength 130 mg/12 to 24 hr and 150 mg/12 to 24 hr (US$), August’2025
Figure 11-26: Kadian - Price Per Unit and Supply Of Strength 200 mg/12 to 24 hr and 200 mg/24 hr (US$), August’2025
Figure 11-27: Xtampza ER - Available Dosage Strengths (mg)
Figure 11-28: Xtampza ER - Price Per Unit and Supply (US$), August’2025
Figure 11-29: Global - Xtampza ER Annual Sales (US$ Million), 2020-2025
Figure 11-30: Global - Xtampza ER Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-31: Global - Xtampza ER Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-32: MS Contin - Available Dosage Strengths (mg)
Figure 11-33: MS Contin - Price Per Unit and Supply (US$), August’2025
Figure 11-34: Embeda - Price Per Unit and Supply (US$), August’2025
Figure 11-35: Zynrelef - Price Per Unit and Supply (US$), August’2025
Figure 11-36: Global - Zynrelef Annual Sales (US$ Million), 2021-2025
Figure 11-37: Global - Zynrelef Quarterly Sales (US$ Million), H1’2025
Figure 11-38: Global - Zynrelef Quarterly Sales (US$ Million), 2024
Figure 11-39: ConZip - Available Dosage Strengths (mg)
Figure 11-40: ConZip - Price Per Unit and Supply (US$), August’2025
Figure 11-41: Generic Hydromorphone - Available Dosage Strengths (mg)
Figure 11-42: Generic Hydromorphone - Price Per Unit and Supply (US$), August’2025
Figure 12-1: Ampyra - Price Per Unit and Supply (US$), August’2025
Figure 12-2: Generic Dalfampridine - Price Per Unit and Supply (US$), August’2025
Figure 12-3: ROW - Fampyra Annual Sales (US$ Million), 2020-2025
Figure 12-4: ROW - Fampyra Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-5: Tecfidera - Available Dosage Strengths (mg)
Figure 12-6: Tecfidera - Price Per Unit and Supply (US$), August’2025
Figure 12-7: Generic Dimethyl Fumarate - Price Per Unit and Supply (US$), August’2025
Figure 12-8: Global - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-9: Global - Tecdifera Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 12-10: Global - Tecdifera Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-11: US - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-12: US - Tecdifera Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 12-13: US - Tecdifera Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-14: ROW - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-15: ROW - Tecdifera Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 12-16: ROW - Tecdifera Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-17: Vumerity - Price Per Unit and Supply (US$), August’2025
Figure 12-18: Global - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-19: Global - Vumerity Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 12-20: Global - Vumerity Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-21: US - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-22: US - Vumerity Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 12-23: US - Vumerity Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-24: ROW - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-25: ROW - Vumerity Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 12-26: ROW - Vumerity Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 12-27: Rayos - Available Dosage Strengths (mg)
Figure 12-28: Rayos - Price Per Unit and Supply (US$), August’2025
Figure 12-29: US - Rayos Annual Sales (US$ Million), 2020-2023
Figure 12-30: Global - Rayos Quarterly Sales (US$ Million), H1’2023
Figure 12-31: Bafiertam - Price Per Unit and Supply (US$), August’2025
Figure 13-1: Glumetza - Available Dosage Strengths (mg)
Figure 13-2: Glumetza - Price Per Unit and Supply (US$), August’2025
Figure 13-3: Generic Metformin - Price Per Unit and Supply Of 500mg (US$), August’2025
Figure 13-4: Generic Metformin - Price Per Unit and Supply Of 1000mg (US$), August’2025
Figure 13-5: Glucotrol XL - Available Dosage Strengths (mg)
Figure 13-6: Glucotrol XL - Price Per Unit and Supply Of Strength 5 mg (US$), August’2025
Figure 13-7: Glucotrol XL - Price Per Unit and Supply Of Strength 10 mg (US$), August’2025
Figure 13-8: Generic Glipizide - Price Per Unit and Supply Of Strength 5 mg (US$), August’2025
Figure 13-9: Generic Glipizide - Price Per Unit and Supply Of Strength 10 mg (US$), August’2025
Figure 13-10: Glucophage XR - Available Dosage Strengths (mg)
Figure 13-11: Glucophage XR - Price Per Unit and Supply Of Strength 10 mg (US$), August’2025
Figure 13-12: Glucophage XR - Price Per Unit and Supply Of Strength 750 mg (US$), August’2025
Figure 13-13: Trijardy XR - Price Per Unit and Supply Of Strengths 10 mg-5 mg-1000 mg and 25 mg-5 mg-1000 mg (US$), August’2025
Figure 13-14: Trijardy XR - Price Per Unit and Supply Of Strengths 10 mg-5 mg-1000 mg and 25 mg-5 mg-1000 mg (US$), August’2025
Figure 13-15: Synjardy XR - Price Per Unit and Supply Of 10 mg-1000 mg and 25 mg-1000 mg (US$), August’2025
Figure 13-16: Synjardy XR - Price Per Unit and Supply Of 5 mg-1000 mg and 12.5 mg-1000 mg (US$), August’2025
Figure 14-1: Procardia XL - Available Dosage Strengths (mg)
Figure 14-2: Procardia XL - Price Per Unit and Supply Of 100 Tablets (US$), August’2025
Figure 14-3: Procardia XL - Price Per Unit and Supply Of 300 Tablets (US$), August’2025
Figure 14-4: Toprol XL - Available Dosage Strengths
Figure 14-5: Toprol XL - Price Per Unit and Supply Of Strengths 25 mg, 50 mg and 200 mg (US$), August’2025
Figure 14-6: Toprol XL - Price Per Unit and Supply Of Strengths 100 mg (US$), August’2025
Figure 14-7: Global - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-8: Global - Toprol XL Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 14-9: US - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-10: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 14-11: EU - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-12: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 14-13: ROW - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-14: ROW - Toprol XL Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 14-15: Verelan PM - Available Dosage Strengths (mg)
Figure 14-16: Verelan PM - Price Per Unit and Supply (US$), August’2025
Figure 14-17: Generic Verapamil - Price Per Unit and Supply (US$), August’2025
Figure 14-18: Cardizem LA - Available Dosage Strengths (mg)
Figure 14-19: Cardizem LA - Price Per Unit and Supply Of 30 Tablets (US$), August’2025
Figure 14-20: Cardizem LA - Price Per Unit and Supply Of 90 Tablets (US$), August’2025
Figure 14-21: Calan SR - Available Dosage Strengths (mg)
Figure 14-22: Calan SR - Price Per Unit and Supply Of 120 mg and 180 mg (US$), August’2025
Figure 14-23: Calan SR - Price Per Unit and Supply Of 240 mg (US$), August’2025
Figure 14-24: Altoprev - Available Dosage Strengths (mg)
Figure 14-25: Altoprev - Price Per Unit and Supply (US$), August’2025
Figure 14-26: Cardura XL - Available Dosage Strengths (mg)
Figure 14-27: Cardura XL - Price Per Unit and Supply (US$), August’2025
Figure 15-1: Apretude - Price Per Unit and Supply (US$), August’2025
Figure 15-2: Cabenuva - Price Per Unit and Supply (US$), August’2025
Figure 15-3: Rukobia - Price Per Unit and Supply (US$), August’2025
Figure 16-1: Qelbree - Price Per Unit and Supply Of Strengths 100 mg and 150 mg (US$), August’2025
Figure 16-2: Qelbree - Price Per Unit and Supply Of Strength 200 mg (US$), August’2025
Figure 16-3: Global - Qelbree Annual Sales (US$ Million), 2021-2023
Figure 16-4: Global - Qelbree Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 16-5: Global - Qelbree Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 16-6: Jornay PM - Available Dosage Strengths (mg)
Figure 16-7: Jornay PM - Price Per Unit and Supply (US$), August’2025
Figure 16-8: Global - Jornay PM Annual Sales (US$ Million), 2024-2025
Figure 16-9: Global - Jornay PM Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 16-10: Global - Jornay PM Quarterly Sales (US$ Million), Q3-Q4’2024
Figure 16-11: Cotempla XR-ODT - Available Dosage Strengths (mg)
Figure 16-12: Cotempla XR-ODT - Price Per Unit and Supply (US$), August’2025
Figure 16-13: Adzenys XR-ODT - Available Dosage Strengths (mg)
Figure 16-14: Adzenys XR-ODT - Price Per Unit and Supply (US$), August’2025
Figure 16-15: Global - Adzenys XR-ODT and Cotempla XR-ODT Annual Sales (US$ Million), 2021-2025
Figure 16-16: Global - Adzenys XR-ODT and Cotempla XR-ODT Quarterly Sales (US$ Million), Q1’2025
Figure 16-17: Global - Adzenys XR-ODT and Cotempla XR-ODT Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 16-18: Intuniv - Available Dosage Strengths (mg)
Figure 16-19: Intuniv - Price Per Unit and Supply (US$), August’2025
Figure 16-20: Global - Intuniv Annual Sales (US$ Million), 2020-2025
Figure 16-21: Global - Intuniv Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 16-22: Focalin XR - Available Dosage Strengths (mg)
Figure 16-23: Focalin XR - Price Per Unit and Supply (US$), August’2025
FigurFigure 17-1: Rinvoq - Available Dosage Strengths (mg)
FigurFigure 17-2: Rinvoq - Price Per Unit and Supply (US$), August’2025
FigurFigure 17-3: Global - Rinvoq Annual Sales (US$ Million), 2020-2025
FigurFigure 17-4: Global - Rinvoq Quarterly Sales (US$ Million), Q1 and Q2’2025
FigurFigure 17-5: Global - Rinvoq Quarterly Sales (US$ Million), Q1-Q4’2024
FigurFigure 17-6: US - Rinvoq Annual Sales (US$ Million), 2020-2025
FigurFigure 17-7: US - Rinvoq Quarterly Sales (US$ Million), Q1 and Q2’2025
FigurFigure 17-8: US - Rinvoq Quarterly Sales (US$ Million), Q1-Q4’2024
FigurFigure 17-9: ROW - Rinvoq Annual Sales (US$ Million), 2020-2025
FigurFigure 17-10: ROW - Rinvoq Quarterly Sales (US$ Million), Q1 and Q2’2025
FigurFigure 17-11: ROW - Rinvoq Quarterly Sales (US$ Million), Q1-Q4’2024
FigurFigure 17-12: Ortikos - Available Dosage Strengths (mg)
FigurFigure 17-13: Ortikos - Price Per Unit and Supply (US$), August’2025
FigurFigure 17-14: Xeljanz XR - Available Dosage Strengths (mg)
FigurFigure 17-15: Xeljanz XR - Price Per Unit and Supply (US$), August’2025
FigurFigure 17-16: Global - Xeljanz XR Annual Sales (US$ Million), 2020-2025
FigurFigure 17-17: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1 and Q2’2025
FigurFigure 17-18: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4’2024
FigurFigure 17-19: US - Xeljanz XR Annual Sales (US$ Million), 2020-2025
FigurFigure 17-20: US - Xeljanz XR Quarterly Sales (US$ Million), Q1 and Q2’2025
FigurFigure 17-21: US - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4’2024
FigurFigure 17-22: ROW - Xeljanz XR Annual Sales (US$ Million), 2020-2025
FigurFigure 17-23: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1 and Q2’2025
FigurFigure 17-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4’2024
FigurFigure 17-25: Mestinon Timespan - Price Per Unit and Supply (US$), August’2025
FigurFigure 17-26: Generic Pyridostigmine - Price Per Unit and Supply (US$), August’2025
FigurFigure 17-27: Symax Duotab - Price Per Unit and Supply (US$), August’2025
Figure 18-1: Aemcolo - Price Per Unit and Supply (US$), August’2025
Figure 18-2: Talicia - Price Per Unit and Supply (US$), August’2025
Figure 19-1: Sublocade - Price Per Unit and Supply (US$), August’2025
Figure 19-2: Global - Sublocade Annual Sales (US$ Million), 2020-2025
Figure 19-3: Global - Sublocade Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 19-4: Global - Sublocade Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 19-5: Sublocade - Price Per Unit and Supply Of Strength 50 mg/mL (US$), August’2025
Figure 19-6: Sublocade - Price Per Unit and Supply Of Strength 355.6 mg/mL (US$), August’2025
Figure 20-1: Astagraf XL - Available Dosage Strengths (mg)
Figure 20-2: Astagraf XL - Price per Unit and Supply (US$), August’2025
Figure 20-3: Envarsus XR - Available Dosage Strengths (mg)
Figure 20-4: Envarsus XR - Price per Unit and Supply Of 30 Tablets (US$), August’2025
Figure 20-5: Envarsus XR - Price per Unit and Supply Of 100 Tablets (US$), August’2025
Figure 21-1: Trokendi XR - Available Dosage Strengths (mg)
Figure 21-2: Trokendi XR - Price per Unit and Supply (US$), August’2025
Figure 21-3: Global - Trokendi XR Annual Sales (US$ Million), 2020-2025
Figure 21-4: Global - Trokendi XR Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 21-5: Global - Trokendi XR Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 21-6: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
Figure 21-7: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 21-8: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 21-9: Keppra XR - Available Dosage Strengths (mg)
Figure 21-10: Keppra XR - Price per Unit and Supply (US$), August’2025
Figure 21-11: Generic levetiracetam - Price per Unit and Supply Of 500 mg (US$), August’2025
Figure 21-12: Keppra XR - Price per Unit and Supply (US$), August’2025
Figure 21-13: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
Figure 21-14: Roweepra XR - Available Dosage Strengths (mg)
Figure 21-15: Roweepra XR - Price per Unit and Supply (US$), August’2025
Figure 21-16: Depakote - Available Dosage Strengths (mg)
Figure 21-17: Depakote - Price per Unit and Supply (US$), August’2025
Figure 21-18: Depakote ER - Available Dosage Strengths (mg)
Figure 21-19: Depakote ER - Price per Unit and Supply (US$), August’2025
Figure 21-20: Depakote Sprinkles - Price per Unit and Supply (US$), August’2025
Figure 22-1: Effexor XR - Available Dosage Strengths (mg)
Figure 22-2: Effexor XR - Price per Unit and Supply Of 30 Capsules (US$), August’2025
Figure 22-3: Effexor XR - Price per Unit and Supply Of 90 Capsules (US$), August’2025
Figure 22-4: Generic Venlafaxine - Price per Unit and Supply Of 37.5 mg (US$), August’2025
Figure 22-5: Generic Venlafaxine - Price per Unit and Supply Of 37.5 mg (US$), August’2025
Figure 22-6: Generic Venlafaxine - Price per Unit and Supply Of 37.5 mg (US$), August’2025
Figure 22-7: Global - Effexor XR Annual Sales (US$ Million), 201-2025
Figure 22-8: Global - Effexor XR Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 22-9: Global - Effexor XR Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 22-10: Xanax XR - Available Dosage Strengths (mg)
Figure 22-11: Xanax XR - Price per Unit and Supply (US$), August’2025
Figure 22-12: Generic Alprazolam - Price per Unit and Supply (US$), August’2025
Figure 22-13: Ambien CR - Available Dosage Strengths (mg)
Figure 22-14: Ambien CR - Price per Unit and Supply (US$), August’2025
Figure 22-15: Generic Zolpidem - Price per Unit and Supply Of 6.25 mg (US$), August’2025
Figure 22-16: Generic Zolpidem - Price per Unit and Supply Of 12.5 mg (US$), August’2025
Figure 23-1: Klor-Con 8 - Price per Unit and Supply (US$), August’2025
Figure 23-2: Generic Potassium Chloride - Price per Unit and Supply Of 8 mEq (US$), August’2025
Figure 23-3: Klor-Con 10 - Price per Unit and Supply (US$), August’2025
Figure 23-4: Klor-Con M10 - Price per Unit and Supply (US$), August’2025
Figure 23-5: Klor-Con M15 - Price per Unit and Supply (US$), August’2025
Figure 23-6: Generic Potassium Chloride - Price per Unit and Supply Of 15 mEq (US$), August’2025
Figure 23-7: Klor-Con M20 - Price per Unit and Supply (US$), August’2025
Figure 24-1: Controlled Drug Delivery System Market - Key Drivers
Figure 24-2: Controlled Drug Delivery System Market - Major Challenges
List of Tables
Table 1-1: Conventional vs. Novel Drug Delivery
Table 1-2: Sustained vs. Controlled Release
Table 5-1: Controlled Release Drugs - Recent US FDA Approvals
